Hyloris Pharmaceuticals (FRA:52U) Pre-Tax Income : €-15.76 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Hyloris Pharmaceuticals's pretax income for the six months ended in Dec. 2023 was €-9.13 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.76 Mil. Hyloris Pharmaceuticals's pretax margin was -551.87%.

During the past 8 years, Hyloris Pharmaceuticals's highest Pretax Margin was -364.41%. The lowest was -6658.24%. And the median was -1776.06%.

Hyloris Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Hyloris Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Pre-Tax Income Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-5.78

-7.15

-11.28

-10.77

-15.76

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial							-3.04	-4.94	-5.82	-6.63	-9.13

Competitive Comparison of Hyloris Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Pre-Tax Income falls into.

Hyloris Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Hyloris Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-16.089	+	0	+	-0.393	+	0.867	+	-0.147
	=	-15.76

Hyloris Pharmaceuticals's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-9.073	+	0	+	-0.293	+	0.301	+	-0.063000000000001
	=	-9.13

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-15.76 Mil.

Hyloris Pharmaceuticals (FRA:52U) Pre-Tax Income Explanation

Hyloris Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-9.128	/	1.654
	=	-551.87%

During the past 8 years, Hyloris Pharmaceuticals's highest Pretax Margin was -364.41%. The lowest was -6658.24%. And the median was -1776.06%.

Hyloris Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (FRA:52U) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (FRA:52U) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

52U:Germany HYL:Belgium

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (FRA:52U) Headlines

No Headlines